Patents by Inventor Sandra Therese Antoinette
Sandra Therese Antoinette has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8506998Abstract: A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.Type: GrantFiled: December 18, 2006Date of Patent: August 13, 2013Assignee: Euro-Celtique S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Hassan Mohammad
-
Publication number: 20090117191Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.Type: ApplicationFiled: May 14, 2008Publication date: May 7, 2009Applicants: PURDUE PHARMA PRODUCTS L.P., NAPP PHARMACEUTICAL GROUP LIMITEDInventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette, Kevin John Smith, Walter Wimmer, Horst Winkler, Udo Hahn, Derek Allan Prater
-
Patent number: 7074430Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.Type: GrantFiled: March 6, 2001Date of Patent: July 11, 2006Assignee: Euro-Celtique S.A.Inventors: Ronald Brown Miller, Sandra Therese Antoinette Malkowska, Walter Wimmer, Udo Hahn, Stewart Thomas Leslie, Kevin John Smith, Horst Winkler, Derek Allan Prater
-
Patent number: 6399096Abstract: A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.Type: GrantFiled: July 27, 1998Date of Patent: June 4, 2002Assignee: Euro-Celtique S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Hassan Mohammad
-
Patent number: 6326027Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.Type: GrantFiled: May 24, 1995Date of Patent: December 4, 2001Assignee: Euro-Celtique S.A.Inventors: Ronald Brown Miller, Sandra Therese Antoinette Malkowska, Walter Wimmer, Udo Hahn, Stewart Thomas Leslie, Kevin John Smith, Horst Winkler, Derek Allan Prater
-
Publication number: 20010036477Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.Type: ApplicationFiled: March 6, 2001Publication date: November 1, 2001Inventors: Ronald Brown Miller, Sandra Therese Antoinette Malkowska, Walter Wimmer, Udo Hahn, Stewart Thomas Leslie, Kevin John Smith, Horst Winkler, Derek Allan Prater
-
Publication number: 20010019725Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.Type: ApplicationFiled: December 19, 2000Publication date: September 6, 2001Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Joanne Heafield, Deborah Challis
-
Patent number: 6254887Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.Type: GrantFiled: July 10, 1996Date of Patent: July 3, 2001Assignee: Euro-Celtique S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Kevin John Smith, Walter Wimmer, Horst Winkler, Udo Hahn, Derek Allan Prater
-
Patent number: 6162467Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.Type: GrantFiled: August 9, 1999Date of Patent: December 19, 2000Assignee: Euro-Celtique, S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Joanne Heafield, Deborah Challis
-
Patent number: 6143328Abstract: Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35 to 150.degree. C.Type: GrantFiled: March 8, 1999Date of Patent: November 7, 2000Assignee: Euro-Celtique, S.A.Inventors: Joanne Heafield, Trevor John Knott, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Ronald Brown Miller, Derek Allan Prater, Kevin John Smith
-
Patent number: 6077532Abstract: A process is provided for preparing a granular pharmnaceutical ion exchange resin composition that is readily dispersible in water by granulating an ion exchange resin, having a pharmacologically active ingredient bound thereto, with a particulate sugar or sugar alcohol. The process is characterised by the use of an aqueous solution of a sugar or sugar alcohol as a granulating medium.Type: GrantFiled: May 8, 1998Date of Patent: June 20, 2000Assignee: Euro-Celtique, S.A.Inventors: Sandra Therese Antoinette Malkowska, Derek Allan Prater, Stewart Thomas Leslie, Adrian Brown, Trevor John Knott
-
Patent number: 5965163Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.Type: GrantFiled: September 30, 1997Date of Patent: October 12, 1999Assignee: Euro-Celtique, S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Trevor John Knott, Joanne Heafield, Deborah Challis
-
Patent number: 5891471Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.Type: GrantFiled: February 27, 1996Date of Patent: April 6, 1999Assignee: Euro-Celtique, S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Treavor John Knott, Deborah Challis, Derek Allan Prater, Joanne Heafield
-
Patent number: 5879705Abstract: Sustained release pharmaceutical formulations containing morphine, or a pharmaceutically acceptable salt thereof, as active ingredient, suitable for administration on a once daily basis, are disclosed. In a first aspect, an orally administrable sustained release unit dosage form gives a peak plasma level at 1.0 to 6 hours after administration. In a second aspect, the formulation provides a W.sub.50 for the M-6-G metabolite for morphine of between 4 and 12 hours. A third aspect concerns the pharmaceutical unit dosage form obtained by compressing multiparticulates comprising a pharmaceutically active substance in a matrix of hydrophobic fusible material having a melting point of from 35.degree. to 150.degree. C.Type: GrantFiled: April 18, 1997Date of Patent: March 9, 1999Assignee: Euro-Celtique S.A.Inventors: Joanne Heafield, Trevor John Knott, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Ronald Brown Miller, Derek Allan Prater, Kevin John Smith
-
Patent number: 5849240Abstract: A process for the manufacture of particles comprises mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixture so as to form agglomerates, breaking the agglomerates to give controlled release particles and optionally continuing the mechanical working with the optional addition of a low percentage of the carrier or diluent.Type: GrantFiled: February 27, 1996Date of Patent: December 15, 1998Assignee: Euro-Celtique, S.A.Inventors: Ronald Brown Miller, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Derek Allan Prater, Treavor John Knott, Joanne Heafield, Deborah Challis
-
Patent number: 5709851Abstract: A stable pharmaceutical composition with reduced irritancy is provided, the composition comprising an aqueous solution of elemental iodine and at least one organic substance which reacts with iodine, whereby iodine loss is controlled by providing a source of iodate ions in an amount sufficient to provide from 0.01% to 0.04% by weight iodate ions, preferably from 0.02% to 0.03% by weight iodate ions.Type: GrantFiled: May 16, 1994Date of Patent: January 20, 1998Assignee: Euro-Celtique, S.A.Inventors: Ian Richard Buxton, Stewart Thomas Leslie, Sandra Therese Antoinette Malkowska, Allan John Miller, Ronald Brown Miller, Derek Allan Prater
-
Patent number: 5670172Abstract: A controlled release composition including spheroid cores of diltiazem or a pharmaceutically acceptable salt thereof and optionally a spheronizing agent, the cores being coated with a controlled release layer, and a method of manufacturing the same, is disclosed. The spheronizing agent when present is preferably microcrystalline cellulose. Ethylcellulose is a preferred release coating. The controlled release coating preferably contains a plasticizer, a surfactant and a tack-modifier.Type: GrantFiled: April 21, 1995Date of Patent: September 23, 1997Assignee: Euro-Celtique, S.A.Inventors: Ian Richard Buxton, Helen Critchley, Stewart Thomas Leslie, Derek Allan Prater, Ronald Brown Miller, Sandra Therese Antoinette Malkowska